Aurora Cannabis Inc.
TSX:ACB.TODrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $414.85M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.32M
Average 0.42M
ACB.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aurora Cannabis Inc.TSX: ACB.TO
Research & Development · Q4 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q4 FY2026 research & development of CA$986K rose 25.6% year over year, behind the +31.9% change in trailing-twelve-month research & development. Sequentially, it fell 43.5% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.
Context
- Research & development amounted to 1.3% of revenue in FY2026, up 0.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +25.6% toward the trailing-twelve-month pace of +31.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2026
- 4.02M CAD
- Year-over-year change
- +9.4%
- 4-year CAGR
- -21.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 4.02M | +9.4% |
| FY2025 | 2025-03-31 | 3.68M | +2.9% |
| FY2024 | 2024-03-31 | 3.57M | -45.6% |
| FY2023 | 2023-03-31 | 6.56M | -36.8% |
| FY2022 | 2022-06-30 | 10.39M | — |
Research & Development vs competitors
How ACB.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.9% is the 2nd highest of 6, against a peer median of -48.4%.
- Research & development amounts to 1.5% of revenue for ACB.TO, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$10.02M CAD | +9.4% | — | 3.7% | |
| LTM Mar 2026 | CA$4.85M CAD | +31.9% | -15.1% | 1.5% | |
| LTM Mar 2026 | CA$1.84M CAD | -59.9% | — | 66.7% | |
| LTM Mar 2026 | CA$267K CAD | +62.8% | — | 0.2% | |
| LTM Mar 2026 | $205.18K USD | -48.4% | -58.4% | 0.4% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | -39.8% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACB.TO) | — | -48.4% | -49.1% | 0.2% | |
Competitors are the stored peer set for ACB.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 221.34M | 233.29M | 270.28M | 343.29M | 320.59M |
| Cost of Revenue | 200.11M | 297.65M | 138.82M | 155.69M | 303.89M |
| Gross Profit | 21.23M | (64.36M) | 131.46M | 187.61M | 16.7M |
| Gross Margin | 9.6% | -27.6% | 48.6% | 54.6% | 5.2% |
| Research & Development | 10.39M | 6.56M | 3.57M | 3.68M | 4.02M |
| Selling, General & Admin | 188.99M | 183.4M | 156.88M | 166.47M | 173.5M |
| Operating Expenses | 252.67M | 189.96M | 177.91M | 182.66M | 179.5M |
| Depreciation & Amortization | 93.66M | 43.57M | 33.07M | 22.55M | 14.19M |
| EBITDA | (1.55B) | (210.74M) | (12.34M) | 51.35M | (162.79M) |
| EBITDA Margin | -702.4% | -90.3% | -4.6% | 15.0% | -50.8% |
| Operating Income | (231.45M) | (254.32M) | (46.45M) | 4.95M | (162.79M) |
| Operating Margin | -104.6% | -109.0% | -17.2% | 1.4% | -50.8% |
| Interest Income | 4.51M | 19M | 12.81M | 11.51M | 5.85M |
| Interest Expense | 71.81M | 39.46M | 14.19M | 8.42M | 1.81M |
| Other Income / Expenses | (1.49B) | (41.1M) | (13.15M) | 15.43M | 106.27M |
| Income Before Tax | (1.72B) | (295.42M) | (59.6M) | 20.38M | (56.52M) |
| Pre-Tax Margin | -777.1% | -126.6% | -22.1% | 5.9% | -17.6% |
| Income Tax Expense | (2.14M) | (20.32M) | (554K) | 4.62M | 2.1M |
| Net Income | (1.72B) | (265.33M) | (69.33M) | 1.59M | (121.76M) |
| Net Margin | -776.0% | -113.7% | -25.6% | 0.5% | -38.0% |
| EPS (Basic) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| EPS (Diluted) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| Weighted Avg Shares | 21.49M | 32.27M | 51.26M | 54.88M | 56.71M |
| Weighted Avg Shares (Diluted) | 21.49M | 32.27M | 51.26M | 55.75M | 56.71M |
Aurora Cannabis Inc.
TSX:ACB.TO
Intrinsic Alpha fair value
Locked
Current Price
$6.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.